On May 20, 2024, collaborative researchers from Guangzhou Sinogen Pharmaceutical, Guangdong University of Technology, Southern Medical University, and other institutions jointly published a research paper titled "Deprivation of metal inhibitors Osteosarcoma growth and metathesis via C1orf112 mediated regulation of mitochondrial functions" online in the international academic journal Cell Death and Disease (IF: 9.0). The paper reports on the genetically engineered oncolytic bacterium SalMet-Vac ^® (SGN1) can specifically target tumor methionine metabolism to inhibit the growth and metastasis of osteosarcoma, and it has been found that methionine restriction can interfere with the mitochondrial function of tumor cells by downregulating the expression of C1orf112 gene, thereby inhibiting the growth mechanism of osteosarcoma. SalMet-Vac ^® has brought a new and effective selection of anti-tumor drugs to the field of osteosarcoma treatment, with enormous potential clinical translational value.

Article DOI: https://doi.org/10.1038/s41419-024-06727-1